Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glutaric aciduria types I and II.

Neil Gordon1

  • 1neil-gordon@doctors.org.uk

Brain & Development
|December 22, 2005
PubMed
Summary

Glutaric aciduria, a genetic disorder, involves deficiencies in enzymes leading to toxic acid buildup. Early diagnosis and treatment with diet and supplements are crucial for managing symptoms and preventing complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid detection of AAV8 binding antibodies in gene therapy candidates: development of a point-of-care approach.

Gene therapy·2025
Same author

Evaluating and implementing machine learning models for personalised mobile health app recommendations.

PloS one·2025
Same author

A 27-Year Experience With Day Surgery Transurethral Resection of the Prostate.

Cureus·2024
Same author

Closing Gaps in Lifestyle Adherence for Secondary Prevention of Coronary Heart Disease.

The American journal of cardiology·2021
Same author

Rare and unusual case of hepatic and disseminated tuberculosis in an immunocompetent patient.

BMJ case reports·2019
Same author

Type and Duration of Exercise in the SAMMPRIS Trial.

The neurologist·2018

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Glutaric aciduria type I (GA-I) results from glutaryl-CoA dehydrogenase deficiency, causing toxic metabolite accumulation.
  • Secondary carnitine deficiency and basal ganglia lesions characterize GA-I, leading to encephalopathic episodes.
  • Glutaric aciduria type II (GA-II) involves deficiencies in electron transport flavoprotein or its oxidoreductase, presenting with variable severity.

Purpose of the Study:

  • To discuss the symptomatology of GA-I, focusing on basal ganglia lesions and encephalopathic episodes.
  • To review diagnostic methods, differential diagnoses, and treatment strategies for both GA-I and GA-II.
  • To highlight the variability in clinical presentation and prognosis for GA-I.

Main Methods:

  • Analysis of urinary organic acids for abnormal acid identification.
  • Enzyme assays on cultured fibroblasts to detect glutaryl-CoA dehydrogenase deficiency.
  • Muscle and liver biopsies for diagnosing GA-II.

Main Results:

  • GA-I diagnosis confirmed by urinary acids and fibroblast enzyme deficiency; prognosis unrelated to enzyme level.
  • GA-II diagnosis confirmed by urinary acids and tissue biopsies.
  • Serious GA-I complications include fluid/blood collections in middle fossae due to bridging vein rupture.

Conclusions:

  • Effective treatment for GA-I involves diet and carnitine supplementation; dystonia may require surgical intervention.
  • GA-II treatment includes diet, carnitine, and riboflavin supplementation.
  • Accurate diagnosis through biochemical analysis and appropriate management are key for both types of glutaric aciduria.

Related Experiment Videos